{"id":"acetylcholine","rwe":[],"_fda":{"id":"687f604e-6337-4927-839c-788ec5db7d5d","set_id":"076587d3-46a0-48e5-9425-f5e1f5847ee3","openfda":{"upc":["0363113600223"],"unii":["AF73293C2R"],"route":["ORAL"],"spl_id":["687f604e-6337-4927-839c-788ec5db7d5d"],"brand_name":["Acetylcholine Chloride Phenolic"],"spl_set_id":["076587d3-46a0-48e5-9425-f5e1f5847ee3"],"package_ndc":["44911-0025-1"],"product_ndc":["44911-0025"],"generic_name":["ACETYLCHOLINE CHLORIDE,"],"product_type":["HUMAN OTC DRUG"],"substance_name":["ACETYLCHOLINE CHLORIDE"],"manufacturer_name":["Energique, Inc."],"is_original_packager":[true]},"purpose":["INDICATIONS: May temporarily relieve symptoms associated with reactions to actylcholine chloride, such as chest congestion with mild constriction. ** **Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."],"version":"4","warnings":["WARNINGS: If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. Do not use if tamper evident seal is broken or missing. Store in a cool, dry place."],"questions":["QUESTIONS: Dist. by Energique, Inc. 201 Apple Blvd Woodbine, IA 51579 800.869.8078"],"effective_time":"20240703","active_ingredient":["ACTIVE INGREDIENTS: (in each drop): 20% of Acetylcholine Chloride 6X, 12X, 30X, 12C, 30C."],"inactive_ingredient":["INACTIVE INGREDIENTS: Demineralized water, 20% Ethanol."],"indications_and_usage":["INDICATIONS: May temporarily relieve symptoms associated with reactions to actylcholine chloride, such as chest congestion with mild constriction. ** **Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."],"dosage_and_administration":["DIRECTIONS: Adults and children 5 to 10 drops orally, 1 time daily or as otherwise directed by a health care professional. If symptoms persist for more than 7 days, consult your health care professional. Consult a physician for use in children under 12 years of age."],"spl_product_data_elements":["Acetylcholine Chloride Phenolic Acetylcholine chloride, ACETYLCHOLINE CHLORIDE ACETYLCHOLINE WATER ALCOHOL"],"keep_out_of_reach_of_children":["KEEP OUT OF REACH OF CHILDREN. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away."],"package_label_principal_display_panel":["PACKAGE LABEL DISPLAY ENERGIQUE SINCE 1987 HOMEOPATHIC REMEDY ACETYLCHOLINE CHLORIDE PHENOLIC 1 fl. oz. (30 ml) Acetylcholine Chloride Phenolic"]},"tags":[{"label":"Cholinergic Receptor Agonist","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Muscarinic acetylcholine receptor M3","category":"target"},{"label":"CHRM3","category":"gene"},{"label":"CHRM2","category":"gene"},{"label":"CHRM1","category":"gene"},{"label":"S01EB09","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Glaucoma","category":"indication"},{"label":"Approved 1970s","category":"decade"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Cholinergic Agents","category":"pharmacology"},{"label":"Cholinergic Agonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DEPRESSION","source":"FDA FAERS","actionTaken":"36 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"35 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"35 reports"},{"date":"","signal":"MALAISE","source":"FDA FAERS","actionTaken":"34 reports"},{"date":"","signal":"RHINORRHOEA","source":"FDA FAERS","actionTaken":"34 reports"},{"date":"","signal":"SINUSITIS","source":"FDA FAERS","actionTaken":"34 reports"},{"date":"","signal":"SLEEP DISORDER","source":"FDA FAERS","actionTaken":"34 reports"},{"date":"","signal":"SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION","source":"FDA FAERS","actionTaken":"34 reports"},{"date":"","signal":"THERAPEUTIC PRODUCT EFFECT INCOMPLETE","source":"FDA FAERS","actionTaken":"34 reports"},{"date":"","signal":"ANXIETY","source":"FDA FAERS","actionTaken":"33 reports"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ACETYLCHOLINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:18:15.562601+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:18:40.749877+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:18:21.368015+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:18:14.684033+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ACETYLCHOLINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:18:21.811383+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:18:13.757311+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:18:32.667206+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:18:13.757343+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:18:23.305402+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Muscarinic acetylcholine receptor M3 agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:18:22.874409+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1184/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:18:22.523739+00:00"}},"allNames":"miochol-e","offLabel":[],"synonyms":["acetylcholine","acetylcholine chloride"],"timeline":[{"date":"1973-10-09","type":"positive","source":"DrugCentral","milestone":"FDA approval"},{"date":"1993-09-22","type":"positive","source":"FDA Orange Book","milestone":"Miochol-E approved — 20MG/VIAL"}],"aiSummary":"Miochol-E, an acetylcholine-based drug marketed by an unspecified company, stimulates the muscarinic acetylcholine receptor M3 to treat symptoms of acetylcholine chloride reactions, with a key composition patent expiring in 2028. Its primary competitive advantage lies in its distinct mechanism of action compared to older off-patent drugs like carbachol and neostigmine, which are widely available as generics. The primary risk is the presence of multiple same-class competitors, including pilocarpine and demecarium, which may limit market share and revenue potential.","brandName":"Miochol-E","ecosystem":[{"indication":"Glaucoma","otherDrugs":[{"name":"echothiophate","slug":"echothiophate","company":"Wyeth Pharms Inc"},{"name":"omidenepag isopropyl","slug":"omidenepag-isopropyl","company":"Santen"}],"globalPrevalence":null}],"mechanism":{"target":"Muscarinic acetylcholine receptor M3","novelty":"Follow-on","targets":[{"gene":"CHRM3","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M3","protein":"Muscarinic acetylcholine receptor M3"},{"gene":"CHRM2","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M2","protein":"Muscarinic acetylcholine receptor M2"},{"gene":"CHRM1","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M1","protein":"Muscarinic acetylcholine receptor M1"},{"gene":"CHRM5","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M5","protein":"Muscarinic acetylcholine receptor M5"},{"gene":"CHRNA4","source":"DrugCentral","target":"Neuronal acetylcholine receptor; alpha4/beta2","protein":"Neuronal acetylcholine receptor subunit alpha-4"},{"gene":"CHRNB2","source":"DrugCentral","target":"Neuronal acetylcholine receptor; alpha4/beta2","protein":"Neuronal acetylcholine receptor subunit beta-2"},{"gene":"CHRM4","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M4","protein":"Muscarinic acetylcholine receptor M4"},{"gene":"CHRNA7","source":"DrugCentral","target":"Neuronal acetylcholine receptor subunit alpha-7","protein":"Neuronal acetylcholine receptor subunit alpha-7"}],"moaClass":"Cholinergic Agonists","modality":"Small Molecule","drugClass":"Cholinergic Receptor Agonist","explanation":"","oneSentence":"","technicalDetail":"Miochol-E acts as a direct agonist at the muscarinic acetylcholine receptor M3, mimicking the action of the neurotransmitter acetylcholine to increase the outflow of aqueous humor from the eye, thereby reducing intraocular pressure."},"commercial":{"launchDate":"1973","_launchSource":"DrugCentral (FDA 1973-10-09, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/65","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ACETYLCHOLINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ACETYLCHOLINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T08:23:46.393559","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-19T23:18:40.750067+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"pilocarpine","drugSlug":"pilocarpine","fdaApproval":"1974-07-29","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"carbachol","drugSlug":"carbachol","fdaApproval":"1972-09-28","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"echothiophate","drugSlug":"echothiophate","fdaApproval":"1960-06-27","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"demecarium","drugSlug":"demecarium","fdaApproval":"1959-08-05","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"neostigmine","drugSlug":"neostigmine","fdaApproval":"2013-05-31","genericCount":16,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fluostigmine","drugSlug":"fluostigmine","fdaApproval":"1957-04-02","relationship":"same-class"}],"genericName":"acetylcholine","indications":{"approved":[{"id":"acetylcholine-symptoms-of-acetylcholine-chlo","name":"Symptoms of acetylcholine chloride reaction","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Not specified","pivotalTrial":null,"restrictions":[],"patientPopulation":"Not specified","diagnosticRequired":null,"brandNameForIndication":"Miochol-E"}],"offLabel":[],"pipeline":[]},"currentOwner":"Novartis","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"pilocarpine","brandName":"pilocarpine","genericName":"pilocarpine","approvalYear":"1974","relationship":"same-class"},{"drugId":"carbachol","brandName":"carbachol","genericName":"carbachol","approvalYear":"1972","relationship":"same-class"},{"drugId":"echothiophate","brandName":"echothiophate","genericName":"echothiophate","approvalYear":"1960","relationship":"same-class"},{"drugId":"demecarium","brandName":"demecarium","genericName":"demecarium","approvalYear":"1959","relationship":"same-class"},{"drugId":"neostigmine","brandName":"neostigmine","genericName":"neostigmine","approvalYear":"2013","relationship":"same-class"},{"drugId":"fluostigmine","brandName":"fluostigmine","genericName":"fluostigmine","approvalYear":"1957","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06435312","phase":"PHASE3","title":"An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis","status":"ENROLLING_BY_INVITATION","sponsor":"UCB Biopharma SRL","startDate":"2024-11-19","conditions":["Generalized Myasthenia Gravis"],"enrollment":8,"completionDate":"2027-11-19"},{"nctId":"NCT06055959","phase":"PHASE2,PHASE3","title":"A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2024-10-16","conditions":["Generalized Myasthenia Gravis"],"enrollment":8,"completionDate":"2026-12-25"},{"nctId":"NCT07498231","phase":"NA","title":"COronoary Microcirculation Analysis NETwork","status":"RECRUITING","sponsor":"Medical University of Bialystok","startDate":"2025-10-10","conditions":["Coronary Artery Disease","Microcirculation Resistance","Microcirculation; Biomarkers; Myocardial Ischemia","Microcirculatory Dysfunction","Microcirculatory Status","Echocardiography","Doppler Echocardiography"],"enrollment":180,"completionDate":"2028-03"},{"nctId":"NCT05403541","phase":"PHASE3","title":"Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immunovant Sciences GmbH","startDate":"2022-06-27","conditions":["Generalized Myasthenia Gravis"],"enrollment":240,"completionDate":"2027-02"},{"nctId":"NCT06607627","phase":"PHASE3","title":"PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-11-13","conditions":["Generalized Myasthenia Gravis","gMG"],"enrollment":12,"completionDate":"2029-01-23"},{"nctId":"NCT07039916","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"Immunovant Sciences GmbH","startDate":"2025-05-27","conditions":["Generalized Myasthenia Gravis"],"enrollment":231,"completionDate":"2028-12"},{"nctId":"NCT07243600","phase":"NA","title":"Improving Neurological Health With Acetylcholine Via Neuroplasticity-based Computerized Exercise in Mild Cognitive Impairment","status":"NOT_YET_RECRUITING","sponsor":"Posit Science Corporation","startDate":"2026-05-05","conditions":["Mild Cognitive Impairment"],"enrollment":84,"completionDate":"2027-05-31"},{"nctId":"NCT07440173","phase":"PHASE4","title":"Phenol and Botulinum Toxin vs Botulinum Toxin Alone for Post-Stroke Upper-Limb Spasticity","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-05-01","conditions":["Spasticity as Sequela of Stroke"],"enrollment":60,"completionDate":"2027-07-15"},{"nctId":"NCT05729243","phase":"PHASE4","title":"Cytisine for Smoking Cessation","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2023-02-08","conditions":["Tobacco Use Disorder","Alcohol Use Disorder","Smoking Cessation"],"enrollment":20,"completionDate":"2025-12-12"},{"nctId":"NCT03953326","phase":"PHASE1,PHASE2","title":"HeartPhone Cancer Survivors Trial 2019","status":"TERMINATED","sponsor":"Penn State University","startDate":"2019-04-23","conditions":["Breast Cancer","Leukemia","Lymphoma"],"enrollment":2,"completionDate":"2020-12-31"},{"nctId":"NCT07215949","phase":"PHASE3","title":"Zilucoplan for Severe gMG Exacerbations","status":"RECRUITING","sponsor":"Miriam Freimer","startDate":"2026-01-20","conditions":["Generalized Myasthenia Gravis (gMG)"],"enrollment":15,"completionDate":"2028-04-01"},{"nctId":"NCT07422818","phase":"NA","title":"Non-invasive Evaluation of Patients With Angina and Non-obstructive Coronary Artery Disease","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2026-03","conditions":["ANOCA - Angina With Non-obstructive Coronary Arteries"],"enrollment":35,"completionDate":"2026-11"},{"nctId":"NCT03442413","phase":"PHASE1","title":"Nicotinic Hepatic Metabolism on Neuroreceptor Substrates of Nicotine Addiction","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2018-06-28","conditions":["Smoking, Tobacco"],"enrollment":13,"completionDate":"2026-11-22"},{"nctId":"NCT05556096","phase":"PHASE3","title":"Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2022-11-21","conditions":["Generalized Myasthenia Gravis"],"enrollment":261,"completionDate":"2027-08-31"},{"nctId":"NCT06887062","phase":"PHASE2","title":"Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2025-03-21","conditions":["Large Vessel Vasculitis","Giant Cell Arteritis (GCA)","Takayasu Arteritis"],"enrollment":60,"completionDate":"2027-07-01"},{"nctId":"NCT07337005","phase":"NA","title":"CompREhensive Diagnostic Assessment of Coronary Endothelial Function Impairment and Vasospasm With CoNtinuous ThErmodilution in Patients With Suspected Coronary Microvascular and Vasomotor Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"Mid and South Essex NHS Foundation Trust","startDate":"2025-12-15","conditions":["Coronary Microvascular Dysfunction (CMD)","Vasospasm, Coronary"],"enrollment":100,"completionDate":"2027-12"},{"nctId":"NCT04872439","phase":"","title":"Novel Antineuronal Antibodies in Gastrointestinal Motility Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2021-04-22","conditions":["Autoimmune Gastrointestinal Dysmotility"],"enrollment":300,"completionDate":"2026-12-31"},{"nctId":"NCT02652065","phase":"NA","title":"Cutaneous Microcirculation and Nervous Sensitivity in Psoriasis","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-02-08","conditions":["Psoriasis"],"enrollment":20,"completionDate":"2018-07-16"},{"nctId":"NCT05288361","phase":"","title":"The DISCOVER INOCA Prospective Multi-center Registry","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2022-09-14","conditions":["Ischemia and No Obstructive Coronary Artery Disease","Coronary Microvascular Dysfunction","Coronary Vasospasm","Endothelial Dysfunction","Microvascular Angina","Chest Pain With Normal Coronary Angiography"],"enrollment":500,"completionDate":"2032-12-31"},{"nctId":"NCT06911372","phase":"PHASE1","title":"The Impact of Gestational Diabetes Mellitus on Cerebral Blood Flow and Cerebrovascular Function After Pregnancy","status":"RECRUITING","sponsor":"Anna Stanhewicz, PhD","startDate":"2025-08-22","conditions":["Gestational Diabetes Mellitus (GDM)","Postpartum Women","Uncomplicated Pregnancy"],"enrollment":84,"completionDate":"2028-04-15"},{"nctId":"NCT06617312","phase":"PHASE2","title":"Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2024-12-05","conditions":["Smoking Cessation","Tobacco Use Disorder"],"enrollment":64,"completionDate":"2026-12"},{"nctId":"NCT06815133","phase":"","title":"Effectiveness and Safety of Zilucoplan Treatment for French Patients With Myasthenia Gravis Over 3 Months","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2025-03-01","conditions":["Myasthenia Gravis"],"enrollment":55,"completionDate":"2026-03-03"},{"nctId":"NCT06520982","phase":"EARLY_PHASE1","title":"Early Neurovascular Adaptations in Aging Women","status":"RECRUITING","sponsor":"University of Missouri-Columbia","startDate":"2024-09-20","conditions":["Women","Sympathetic Nervous System","Aging","Blood Flow"],"enrollment":64,"completionDate":"2028-06-30"},{"nctId":"NCT07227740","phase":"","title":"Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury","status":"RECRUITING","sponsor":"Craig Hospital","startDate":"2025-07-15","conditions":["Spinal Cord Injuries","Endothelial Dysfunction","Testosterone Deficiency"],"enrollment":48,"completionDate":"2028-07-14"},{"nctId":"NCT07227727","phase":"","title":"Endothelial Dysfunction After SCI","status":"RECRUITING","sponsor":"Craig Hospital","startDate":"2025-07-31","conditions":["Spinal Cord Injuries","Endothelial Dysfunction"],"enrollment":40,"completionDate":"2027-07-30"},{"nctId":"NCT02725060","phase":"NA","title":"Autoimmune Basis for Postural Tachycardia Syndrome","status":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","startDate":"2016-02","conditions":["Postural Orthostatic Tachycardia Syndrome","Postural Tachycardia Syndrome","Tachycardia","Arrhythmias, Cardiac","Autonomic Nervous System Diseases","Orthostatic Intolerance","Cardiovascular Diseases","Primary Dysautonomias"],"enrollment":58,"completionDate":"2026-12"},{"nctId":"NCT06298552","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis","status":"ACTIVE_NOT_RECRUITING","sponsor":"argenx","startDate":"2024-04-16","conditions":["Generalized Myasthenia Gravis","gMG","Myasthenia Gravis, Generalized","Myasthenia Gravis"],"enrollment":119,"completionDate":"2027-06"},{"nctId":"NCT02689466","phase":"","title":"Cholinergic Receptor Imaging in Dystonia","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2016-12-16","conditions":["Cervical Dystonia","Dystonia","Movement Disorder","Focal Dystonia"],"enrollment":31,"completionDate":"2021-11-26"},{"nctId":"NCT02966665","phase":"PHASE1","title":": Vascular Function in Health and Disease","status":"RECRUITING","sponsor":"Russell Richardson","startDate":"2008-09","conditions":["Chronic Obstructive Pulmonary Disease","Pulmonary Artery Hypertension","Heart Failure","Hypertension"],"enrollment":420,"completionDate":"2026-08"},{"nctId":"NCT07192744","phase":"NA","title":"Rotigaptide in Endothelial Dysfunction?","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2008-09-19","conditions":["Ischaemic Heart Diseases"],"enrollment":12,"completionDate":"2009-12-31"},{"nctId":"NCT03062878","phase":"","title":"The Effects of Anthracycline-based Chemotherapy on Peripheral Vascular Function","status":"COMPLETED","sponsor":"Carl Ade, M.S., Ph.D.","startDate":"2017-02-01","conditions":["Breast Cancer","Lymphoma","Chemotherapy Effect"],"enrollment":60,"completionDate":"2018-08-01"},{"nctId":"NCT04042298","phase":"","title":"Microvascular Function in Patients Undergoing 5-Fluorouracil Chemotherapy","status":"COMPLETED","sponsor":"Kansas State University","startDate":"2019-06-25","conditions":["Gastrointestinal Cancer","Head and Neck Cancer","Breast Cancer","Chemotherapy Effect","5-Fluorouracil Toxicity"],"enrollment":62,"completionDate":"2023-06-01"},{"nctId":"NCT05793567","phase":"","title":"A Study of Microcirculatory Function in Type 2 Myocardial Infarction (T2MI)","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-08","conditions":["Myocardial Infarction","Coronary Microvascular Disease"],"enrollment":52,"completionDate":"2027-04"},{"nctId":"NCT05630612","phase":"PHASE2","title":"ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Edinburgh","startDate":"2022-12-08","conditions":["ANCA Associated Vasculitis","Cardiovascular Diseases","Kidney Diseases"],"enrollment":32,"completionDate":"2027-09-01"},{"nctId":"NCT06499844","phase":"EARLY_PHASE1","title":"Comparing Approaches to Assess Nitric Oxide-dependent Cutaneous Vasodilation","status":"RECRUITING","sponsor":"University of Iowa","startDate":"2024-08-01","conditions":["Endothelial Function"],"enrollment":56,"completionDate":"2026-09"},{"nctId":"NCT01832623","phase":"NA","title":"Vitamin D, Bones, Nutritional and Cardiovascular Status","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2013-02","conditions":["Vitamin D"],"enrollment":100,"completionDate":"2016-07"},{"nctId":"NCT06810765","phase":"PHASE2","title":"Trifecta Research Study","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2025-09","conditions":["PTSD - Post Traumatic Stress Disorder","Cognitive Dysfunction","Brain Trauma","Brain Injuries"],"enrollment":0,"completionDate":"2027-12"},{"nctId":"NCT07103317","phase":"","title":"Comprehensive Coronary Physiology in Patients With Angina With Nonobstructive Coronary Arteries - Czech Republic","status":"RECRUITING","sponsor":"University Hospital, Motol","startDate":"2023-04-20","conditions":["ANOCA","ANOCA - Angina With Non-obstructive Coronary Arteries","MINOCA","Microvascular Dysfunction","Microvascular Angina","Vasospastic Angina","Acetylcholine"],"enrollment":1000,"completionDate":"2030-01-01"},{"nctId":"NCT06518941","phase":"PHASE2","title":"An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia Nervosa","status":"NOT_YET_RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2026-06","conditions":["Anorexia Nervosa"],"enrollment":10,"completionDate":"2027-12"},{"nctId":"NCT06043310","phase":"","title":"Estrogen and Microvascular Function","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-10-12","conditions":["Estrogen","Cardiovascular Diseases","Microvasculature","Oral Contraceptive Use"],"enrollment":45,"completionDate":"2031-12"},{"nctId":"NCT05355311","phase":"PHASE1","title":"Enhancing the Effects of Alcohol Treatment With L-Carnitine","status":"COMPLETED","sponsor":"Brown University","startDate":"2024-09-27","conditions":["Alcohol Use Disorder"],"enrollment":24,"completionDate":"2025-05-31"},{"nctId":"NCT05193968","phase":"NA","title":"Hot Flashes and Neurovascular Function in Women","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-02-24","conditions":["Hot Flashes","Menopause","Vasomotor System; Labile"],"enrollment":120,"completionDate":"2026-12"},{"nctId":"NCT05653973","phase":"EARLY_PHASE1","title":"Prenatal Aspirin and Postpartum Vascular Function","status":"RECRUITING","sponsor":"Anna Stanhewicz, PhD","startDate":"2023-01-03","conditions":["Preeclampsia","Microvascular Function"],"enrollment":60,"completionDate":"2027-07-30"},{"nctId":"NCT04101968","phase":"","title":"The GBA Multimodal Study in Parkinson's Disease","status":"RECRUITING","sponsor":"Pacific Parkinson's Research Centre","startDate":"2019-05-01","conditions":["Parkinson Disease","GBA Gene Mutation","Gaucher Disease"],"enrollment":25,"completionDate":"2025-12-30"},{"nctId":"NCT06995573","phase":"PHASE1,PHASE2","title":"A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"NSC-Therapeutics","startDate":"2025-06-30","conditions":["Alzheimer Disease"],"enrollment":90,"completionDate":"2026-09-30"},{"nctId":"NCT03654066","phase":"PHASE4","title":"Botox or Botox With Esophageal Dilation in Patients With Achalasia","status":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","startDate":"2019-05-13","conditions":["Achalasia"],"enrollment":50,"completionDate":"2026-06"},{"nctId":"NCT05946785","phase":"EARLY_PHASE1","title":"Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes","status":"RECRUITING","sponsor":"Anna Stanhewicz, PhD","startDate":"2023-07-01","conditions":["Gestational Diabetes","Vascular Endothelial Function"],"enrollment":28,"completionDate":"2027-06-01"},{"nctId":"NCT05946798","phase":"EARLY_PHASE1","title":"Role of NADPH Oxidase in Microvascular Dysfunction Following GDM","status":"RECRUITING","sponsor":"Anna Stanhewicz, PhD","startDate":"2023-08-30","conditions":["Gestational Diabetes","Oxidative Stress","Vascular Endothelial Function"],"enrollment":40,"completionDate":"2028-06-01"},{"nctId":"NCT04001647","phase":"EARLY_PHASE1","title":"Targeting ER Stress in Vascular Dysfunction","status":"TERMINATED","sponsor":"Colorado State University","startDate":"2019-06-01","conditions":["Vasodilation","Arterial Stiffness"],"enrollment":17,"completionDate":"2022-08-16"},{"nctId":"NCT05034263","phase":"","title":"Imaging a Cholinergic Biomarker of Cognition in Parkinson's Disease","status":"TERMINATED","sponsor":"Stony Brook University","startDate":"2021-05-27","conditions":["Parkinson's Disease"],"enrollment":6,"completionDate":"2024-05-27"},{"nctId":"NCT06854302","phase":"","title":"Angina After PCI: a Systems Medicine Study","status":"ENROLLING_BY_INVITATION","sponsor":"NHS National Waiting Times Centre Board","startDate":"2024-09-17","conditions":["Angina (Stable)","Ischemic Heart Disease (IHD)"],"enrollment":600,"completionDate":"2028-10-01"},{"nctId":"NCT05413655","phase":"PHASE2","title":"A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease","status":"RECRUITING","sponsor":"Excelsior","startDate":"2022-08-08","conditions":["Alzheimer Disease"],"enrollment":120,"completionDate":"2027-02"},{"nctId":"NCT05125029","phase":"PHASE4","title":"Botulinum Toxin in Raynaud's Phenomenon","status":"RECRUITING","sponsor":"Emory University","startDate":"2022-02-10","conditions":["Raynaud Phenomenon"],"enrollment":36,"completionDate":"2025-12"},{"nctId":"NCT06811142","phase":"EARLY_PHASE1","title":"Early Botulinum Toxin for Muscle Stiffness Reduction in First-Time Stroke Patients: Improving Recovery and Independence","status":"ACTIVE_NOT_RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2025-01-28","conditions":["Spasticity","Stroke","Neurological Rehabilitation"],"enrollment":200,"completionDate":"2030-02-01"},{"nctId":"NCT04755595","phase":"PHASE2","title":"Combination Facial Aesthetic Treatment in Millennials","status":"COMPLETED","sponsor":"State University of New York - Downstate Medical Center","startDate":"2021-03-09","conditions":["Dermatological Non-Disease"],"enrollment":20,"completionDate":"2021-05-19"},{"nctId":"NCT06704334","phase":"PHASE4","title":"The Study of Ginkgo Leaf Dropping Pills and Huperzine a Injection Combined with Median Nerve Electrical Stimulation in the Treatment of Cognitive Impairment After Brain Injury","status":"RECRUITING","sponsor":"Wanbangde Pharmaceutical Group Co., LTD","startDate":"2024-04-01","conditions":["Cognitive Impairment After Brain Injury"],"enrollment":50,"completionDate":"2026-12-31"},{"nctId":"NCT02196155","phase":"NA","title":"Botulinum Toxin A Versus Steroids for the Treatment of Chronic Plantar Fasciitis","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2016-07","conditions":["Plantar Fasciitis"],"enrollment":54,"completionDate":"2026-12"},{"nctId":"NCT06070662","phase":"","title":"Non-invasive Diagnosis of Coronary Microvascular Disease: Pilot Study","status":"RECRUITING","sponsor":"University of Leicester","startDate":"2023-11-01","conditions":["Microvascular Angina"],"enrollment":20,"completionDate":"2025-12"},{"nctId":"NCT06125392","phase":"","title":"Multicenter Registry on Microvascular Dysfunction - Searching a New Ach Spasm Definition","status":"RECRUITING","sponsor":"Johannes Gutenberg University Mainz","startDate":"2023-09-30","conditions":["Coronary Microvascular Disease","Coronary Vasospasm"],"enrollment":1000,"completionDate":"2028-08-31"},{"nctId":"NCT03193294","phase":"NA","title":"CORonary MICrovascular Angina (CorMicA)","status":"COMPLETED","sponsor":"NHS National Waiting Times Centre Board","startDate":"2016-11-07","conditions":["Angina, Stable","Coronary Vasospasm","Coronary Circulation","Coronary Syndrome","Microvascular Angina","Coronary Disease"],"enrollment":151,"completionDate":"2019-11-06"},{"nctId":"NCT03477890","phase":"NA","title":"Coronary Microvascular Function and CT Coronary Angiography (CorCTCA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"NHS National Waiting Times Centre Board","startDate":"2017-08-31","conditions":["Angina, Stable","Angina Pectoris, Variant","Microvascular Angina"],"enrollment":250,"completionDate":"2033-08-31"},{"nctId":"NCT05337891","phase":"","title":"Sensitivity of Repetitive Nerve Stimulation Performed in the Evening vs in the Morning in Myasthenia Gravis","status":"RECRUITING","sponsor":"Jagiellonian University","startDate":"2022-06-03","conditions":["Myasthenia Gravis"],"enrollment":40,"completionDate":"2026-09-01"},{"nctId":"NCT05243251","phase":"PHASE3","title":"Olanzapine Anorexia Cachexia","status":"COMPLETED","sponsor":"Cairo University","startDate":"2021-12-25","conditions":["Anorexia"],"enrollment":164,"completionDate":"2022-12-14"},{"nctId":"NCT06443151","phase":"","title":"Role of Endothelial Function in SCI CVD Risk","status":"RECRUITING","sponsor":"Craig Hospital","startDate":"2024-09-01","conditions":["Spinal Cord Injuries","Cardiovascular Diseases","Endothelial Dysfunction"],"enrollment":60,"completionDate":"2027-03-30"},{"nctId":"NCT04055467","phase":"PHASE1","title":"Brain Imaging in Tobacco Smokers During a Quit Attempt","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2019-12-16","conditions":["Tobacco Use Disorder","Tobacco Smoking"],"enrollment":15,"completionDate":"2022-11-30"},{"nctId":"NCT05122780","phase":"PHASE4","title":"Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-07-01","conditions":["Myocardial Infarction With Non-Obstructive Coronary Arteries"],"enrollment":120,"completionDate":"2025-07"},{"nctId":"NCT04744636","phase":"PHASE1","title":"Vascular Function and Biomarker Assessments in Healthy Volunteers and in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2017-04-03","conditions":["Type 2 Diabetes Mellitus"],"enrollment":100,"completionDate":"2018-09-15"},{"nctId":"NCT06281067","phase":"NA","title":"Reassessment of myocardIAL Bridge TOwards PeRsOnalized Medicine","status":"RECRUITING","sponsor":"Azienda Ospedaliero Universitaria Maggiore della Carita","startDate":"2023-12-15","conditions":["Myocardial Bridge"],"enrollment":500,"completionDate":"2026-01-01"},{"nctId":"NCT06487416","phase":"PHASE1","title":"A Trial to Assess the Bioequivalence of Tiotropium Bromide Inhalation Powder in Healthy Adult Participants Under Fasting Conditions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-06-10","conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"enrollment":186,"completionDate":"2024-10"},{"nctId":"NCT06482021","phase":"NA","title":"Comparative Effectiveness Of Low Extra-Corporeal Shock Wave Versus Acetylcholine Iontophoresis On Type2 Diabetic Neuropathy","status":"NOT_YET_RECRUITING","sponsor":"South Valley University","startDate":"2024-07-10","conditions":["Diabetic Nephropathy"],"enrollment":80,"completionDate":"2024-10-01"},{"nctId":"NCT06454084","phase":"NA","title":"Investigation of Endothelium-dependent Vasodilation in Human Gingiva","status":"ACTIVE_NOT_RECRUITING","sponsor":"Semmelweis University","startDate":"2023-09-01","conditions":["Vasodilation","Oral Soft Tissue Conditions"],"enrollment":80,"completionDate":"2025-12-31"},{"nctId":"NCT03579966","phase":"PHASE3","title":"Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)","status":"TERMINATED","sponsor":"Catalyst Pharmaceuticals, Inc.","startDate":"2018-06-11","conditions":["Myasthenia Gravis, MuSK","AChR Myasthenia Gravis"],"enrollment":63,"completionDate":"2022-08-05"},{"nctId":"NCT01813032","phase":"","title":"Comparison of Vascular Function in Emergency Service Professionals","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2012-04","conditions":["Vascular Function","Atherothrombosis"],"enrollment":36,"completionDate":"2013-04"},{"nctId":"NCT01805063","phase":"","title":"Effect of Fire Suppression and Emergency Duties on Vascular Function","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2012-01-09","conditions":["Vascular Function","Atherothrombosis"],"enrollment":30,"completionDate":"2016-12-31"},{"nctId":"NCT06392633","phase":"NA","title":"SURGERY VS BOTULINUM TOXIN ON QUALITY OF LIFE IN STROKE PATIENTS: RANDOMIZED TRIAL","status":"RECRUITING","sponsor":"Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental","startDate":"2021-01-01","conditions":["Stroke"],"enrollment":44,"completionDate":"2024-12-01"},{"nctId":"NCT04124939","phase":"PHASE4","title":"Is 10 Injections of Bladder Botox Less Painful Than 20 Injections?","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2019-11-10","conditions":["Overactive Bladder"],"enrollment":41,"completionDate":"2023-02-23"},{"nctId":"NCT05018117","phase":"EARLY_PHASE1","title":"Effects of Nicotine and Attention on Frequency Tuning in Auditory Cortex","status":"RECRUITING","sponsor":"University of California, Berkeley","startDate":"2022-06-06","conditions":["Aging"],"enrollment":48,"completionDate":"2025-12-31"},{"nctId":"NCT05164640","phase":"NA","title":"Ischemia in Patients With Non-obstructive Disease (INOCA) in Italy INOCA IT Multicenter Registry\"","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2021-12-01","conditions":["Cardiac Ischemia"],"enrollment":200,"completionDate":"2024-02-29"},{"nctId":"NCT06326671","phase":"PHASE1","title":"A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-02-28","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":39,"completionDate":"2024-04"},{"nctId":"NCT03446612","phase":"PHASE2","title":"Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-01-10","conditions":["Anaemia"],"enrollment":6,"completionDate":"2019-05-29"},{"nctId":"NCT03912012","phase":"NA","title":"Pilot Study DiaDEP","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2019-07-09","conditions":["Diabetes Mellitus, Type 1","Type1diabetes"],"enrollment":23,"completionDate":"2020-11-20"},{"nctId":"NCT05714241","phase":"","title":"BIOmarkers and PLAtelet Function Assessment in Myocardial Ischemia and Non Obstructive Coronary Arteries Study","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2022-02-01","conditions":["Ischemia With no Obstructive Coronary Artery Disease"],"enrollment":200,"completionDate":"2027-03-01"},{"nctId":"NCT05714319","phase":"","title":"Intracoronary Provocative Test With Acetylcholine in Patients With INOCA and MINOCA","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2023-01-12","conditions":["Myocardial Infarction With Non-Obstructive Coronary Artery","Ischemia With Non-Obstructive Coronary Artery"],"enrollment":600,"completionDate":"2028-01-12"},{"nctId":"NCT04258852","phase":"NA","title":"Understanding Factors That Influence Electronic Cigarette Nicotine Delivery Through PET Imaging of Beta-2 Nicotinic Acetylcholine Receptors","status":"WITHDRAWN","sponsor":"Yale University","startDate":"2022-12-30","conditions":["Electronic Cigarette Use"],"enrollment":0,"completionDate":"2025-02-01"},{"nctId":"NCT02987465","phase":"","title":"Evaluating the Effect of Standard-of-care Erythropoiesis-stimulating Agents on Forearm Blood Flow in Nondialysis-dependent Subjects With Anaemia Associated With Chronic Kidney Disease.","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-02-20","conditions":["Cardiovascular Diseases","Chronic Kidney Disease"],"enrollment":29,"completionDate":"2018-05-21"},{"nctId":"NCT06219590","phase":"NA","title":"Acetylcholine Iontophoresis As A New Challenge With Type 2 Diabetic Peripheral Neuropathy: A Possible New Therapy","status":"UNKNOWN","sponsor":"South Valley University","startDate":"2023-10-28","conditions":["Type 2 Diabetes Mellitus","Peripheral Neuropathy"],"enrollment":80,"completionDate":"2024-01-30"},{"nctId":"NCT03647137","phase":"","title":"Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2016-06-07","conditions":["Parkinson's Disease"],"enrollment":53,"completionDate":"2021-05-26"},{"nctId":"NCT06180252","phase":"","title":"PET Study of Acetylcholine Esterase Activity in Alzheimer's Disease","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2004-05-12","conditions":["Alzheimer Disease"],"enrollment":30,"completionDate":"2008-01-29"},{"nctId":"NCT02008292","phase":"NA","title":"Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors","status":"COMPLETED","sponsor":"Yale University","startDate":"2013-09","conditions":["Smoking","Schizophrenia"],"enrollment":80,"completionDate":"2021-12"},{"nctId":"NCT06089031","phase":"","title":"Belgian Registry on Coronary Function Testing","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2021-10-18","conditions":["Coronary Microvascular Dysfunction","Coronary Artery Vasospasm"],"enrollment":650,"completionDate":"2026-12-31"},{"nctId":"NCT06055101","phase":"NA","title":"Regional Anaesthesia","status":"COMPLETED","sponsor":"Reham Ali Abdelhaleem Abdelrahman","startDate":"2019-01-03","conditions":["Anesthesia, Obstetric"],"enrollment":54,"completionDate":"2023-04-04"},{"nctId":"NCT04649866","phase":"NA","title":"Coronary Artery Disease in Patients With Friedreich's Ataxia","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2021-02-15","conditions":["Friedreich Ataxia"],"enrollment":7,"completionDate":"2023-09-01"},{"nctId":"NCT00573027","phase":"NA","title":"Heart Disease of the Small Arteries in Women and Men","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2005-11","conditions":["Heart Disease"],"enrollment":634,"completionDate":"2040-01"},{"nctId":"NCT05389813","phase":"PHASE2,PHASE3","title":"Comparison Between Oxycodone and Pregabalin as Preemptive Analgesia","status":"UNKNOWN","sponsor":"An-Najah National University","startDate":"2021-08-15","conditions":["Anesthesia"],"enrollment":150,"completionDate":"2024-05-01"},{"nctId":"NCT00921856","phase":"NA","title":"Abnormal Coronary Vasomotion in Patients With Suspected Coronary Artery Disease (CAD)","status":"UNKNOWN","sponsor":"Peter Ong, MD","startDate":"2007-11","conditions":["Coronary Vasospasm","Microvascular Angina","Coronary Artery Disease"],"enrollment":1000,"completionDate":"2025-12"},{"nctId":"NCT05863286","phase":"NA","title":"Assessment of Botulinum Toxin Injection for Treatment of Temporomandibular Joint Dislocation","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2022-12-30","conditions":["Dislocation of Temporomandibular Joint TMJ","Subluxation of Temporomandibular Joint"],"enrollment":28,"completionDate":"2024-03-31"},{"nctId":"NCT04374500","phase":"EARLY_PHASE1","title":"Leptin Infusion and Endothelial Vasomotor Response","status":"COMPLETED","sponsor":"Stefan Soderberg","startDate":"2006-01-01","conditions":["Endothelial Dysfunction","Obesity","Vasodilation","Venous Occlusion Plethysmography"],"enrollment":103,"completionDate":"2006-12-20"},{"nctId":"NCT04773899","phase":"NA","title":"COVID-19 Associated Endothelial Dysfunction Study","status":"COMPLETED","sponsor":"University Hospital, Angers","startDate":"2021-10-22","conditions":["Covid19","Microcirculation"],"enrollment":75,"completionDate":"2022-12-21"},{"nctId":"NCT03508869","phase":"NA","title":"Mirvaso® Gel and Dysport® for Erythema and Flushing of Rosacea","status":"TERMINATED","sponsor":"Skin Laser & Surgery Specialists","startDate":"2016-09-27","conditions":["Erythema and Flushing Associated With Rosacea"],"enrollment":5,"completionDate":"2017-09-20"},{"nctId":"NCT02678377","phase":"PHASE4","title":"The SLIM Study: Sling and Botox® Injection for Mixed Urinary Incontinence","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2016-02","conditions":["Mixed Urinary Incontinence","Stress Urinary Incontinence","Urgency Incontinence"],"enrollment":100,"completionDate":"2021-07-26"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral"},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147690","MMSL":"4126","NDDF":"001697","UNII":"N9YNS0M02X","VUID":"4019594","CHEBI":"CHEBI:15355","VANDF":"4019546","INN_ID":"438","RXNORM":"194","UMLSCUI":"C0001041","chemblId":"CHEMBL1184","ChEMBL_ID":"CHEMBL1184","KEGG_DRUG":"D00999","DRUGBANK_ID":"DB03128","PDB_CHEM_ID":" ACH","PUBCHEM_CID":"187","SNOMEDCT_US":"13525006","IUPHAR_LIGAND_ID":"294","SECONDARY_CAS_RN":"60-31-1","MESH_DESCRIPTOR_UI":"D000109"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Novartis","relationship":"Current Owner"}],"publicationCount":89752,"therapeuticAreas":["Ophthalmology"],"atcClassification":{"source":"DrugCentral","atcCode":"S01EB09","allCodes":["S01EB09"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Novartis","companyId":"","modality":"Small molecule","firstApprovalDate":"1973","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1995-08-18T00:00:00.000Z","mah":"BAUSCH AND LOMB","brand_name_local":null,"application_number":"NDA020213"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":1},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-19T23:18:40.750067+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}